Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $21.92, for a total transaction of $65,760.00. Following the completion of the sale, the vice president now owns 3,270 shares of the company’s stock, valued at $71,678.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Brent Johnson also recently made the following trade(s):

  • On Monday, October 14th, Brent Johnson sold 1,902 shares of Iradimed stock. The stock was sold at an average price of $21.82, for a total transaction of $41,501.64.
  • On Friday, October 11th, Brent Johnson sold 1,300 shares of Iradimed stock. The stock was sold at an average price of $21.63, for a total transaction of $28,119.00.
  • On Wednesday, October 9th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.99, for a total transaction of $65,970.00.
  • On Monday, October 7th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $22.34, for a total transaction of $44,680.00.
  • On Friday, October 4th, Brent Johnson sold 4,000 shares of Iradimed stock. The stock was sold at an average price of $21.70, for a total transaction of $86,800.00.
  • On Wednesday, October 2nd, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.00, for a total transaction of $21,000.00.
  • On Monday, September 30th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.51, for a total transaction of $21,510.00.
  • On Friday, September 27th, Brent Johnson sold 2,213 shares of Iradimed stock. The stock was sold at an average price of $21.77, for a total transaction of $48,177.01.
  • On Wednesday, September 25th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $22.84, for a total transaction of $68,520.00.
  • On Monday, September 23rd, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $22.25, for a total transaction of $44,500.00.

IRMD stock traded up $0.91 on Wednesday, reaching $22.68. 62,678 shares of the company were exchanged, compared to its average volume of 68,492. Iradimed Corp has a 12 month low of $16.68 and a 12 month high of $30.90. The stock’s fifty day moving average price is $21.15 and its 200 day moving average price is $22.01. The firm has a market capitalization of $257.87 million, a PE ratio of 52.74 and a beta of 1.56. The company has a debt-to-equity ratio of 0.06, a current ratio of 10.29 and a quick ratio of 9.39.

Iradimed (NASDAQ:IRMD) last announced its earnings results on Tuesday, July 30th. The medical equipment provider reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.05. Iradimed had a net margin of 23.92% and a return on equity of 14.78%. The business had revenue of $9.23 million for the quarter, compared to analyst estimates of $8.91 million. As a group, research analysts expect that Iradimed Corp will post 0.67 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. HM Payson & Co. bought a new position in Iradimed during the second quarter worth $89,000. Charles Schwab Investment Management Inc. increased its position in Iradimed by 34.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 10,500 shares of the medical equipment provider’s stock worth $215,000 after acquiring an additional 2,666 shares during the period. Marshall Wace LLP bought a new position in Iradimed during the first quarter worth $241,000. Morgan Stanley increased its position in Iradimed by 14.3% during the second quarter. Morgan Stanley now owns 13,118 shares of the medical equipment provider’s stock worth $268,000 after acquiring an additional 1,637 shares during the period. Finally, Strs Ohio increased its position in Iradimed by 7.5% during the second quarter. Strs Ohio now owns 20,100 shares of the medical equipment provider’s stock worth $411,000 after acquiring an additional 1,400 shares during the period. 30.91% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently weighed in on IRMD shares. Zacks Investment Research cut shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. ValuEngine upgraded shares of Iradimed from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Read More: Cost of Debt

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.